About Us

Molecular Targeting Technologies, Inc. (MTTI)

Our Mission: Translate novel radiopharmaceuticals for treatment and diagnosis of underserved diseases.

Our Targets:
Therapeutics, supported by published data and ongoing Phase I clinical trials:

EBTATE (177Lu-EB-DOTA-TATE), a neuroendocrine tumor therapy (NET). EBTATE shows several-fold increase of blood half-life and enhanced tumor uptake over existing peptide receptor radionuclide therapy (PRRT).

131 I-SapC-DOPS, a nanovesicle for glioblastoma multiforme (GBM), readily crosses the blood tumor/brain barrier delivering a dual killing effect to brain tumors. Preclinical studies demonstrated that the radioiodinated SapC-DOPS nanovesicle improves median survival by 43% compared with SapC-DOPS alone..


TDURA (99mTc-duramycin), targets cell death in multiple applications including cardiotoxicity, atherosclerotic plaque, systemic inflammatory response syndrome (SIRS) and organ transplant rejection. A clinical study for early detection of tumor response to treatment will begin in 4Q 2019.

18F-glucaric acid is being developed for detecting stroke and acute MI. 99mTc-glucarate, was effective for MI detection in a phase II clinical trial.
*See pipeline page